2024
Comparison of agranulocytosis and anti‐neutrophil cytoplasmic antibody‐associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database
Han J, Lee J, Jung Y, Kim M, Lee S, Kronbichler A, Tizaoui K, Koyanagi A, Kim E, Song K, Chae H, Yon D, Shin J, Smith L. Comparison of agranulocytosis and anti‐neutrophil cytoplasmic antibody‐associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database. Fundamental & Clinical Pharmacology 2024, 38: 780-788. PMID: 38342499, DOI: 10.1111/fcp.12991.Peer-Reviewed Original ResearchConceptsAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitisAdverse drug reactionsAssociated with MMICases of adverse drug reactionsAntithyroid drugsAnti-neutrophil cytoplasmic antibody-associated vasculitisAntibody (ANCA)-associated vasculitisAssociated with high morbidityCase/non-case analysisCases of agranulocytosisAntibody-associated vasculitisAdverse drug effectsAgranulocytosis casesAnti-neutrophilDrug withdrawalAgranulocytosisHigh morbidityCase/non-caseDrug effectsPharmacovigilance databaseIndividual case safety reportsDrug reactionsPropylthiouracilDisproportionality analysisPharmacovigilance studies
2022
Adverse drug effects across patients with heart failure: a systematic review.
Butzner M, Riello RJ, Sarocco P, Desai N. Adverse drug effects across patients with heart failure: a systematic review. The American Journal Of Managed Care 2022, 28: e113-e120. PMID: 35404555, DOI: 10.37765/ajmc.2022.88844.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAdverse drug effectsAngiotensin receptor blockersMineralocorticoid receptor antagonistsDrug-related adverse effectsRenal impairmentHeart failureMedical therapyDrug effectsAngiotensin receptor neprilysin inhibitorAdverse effectsReduced ejection fractionAdditional real-world evidenceReal-world evidenceKey search termsSystematic literature reviewReceptor blockersAdult patientsEjection fractionACE inhibitorsReceptor antagonistClinical trialsOvid MEDLINEClinical KeyΒ-blockers
2019
High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?
Kitchlu A, Shirali A. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best? Journal Of Onco-Nephrology 2019, 3: 11-18. DOI: 10.1177/2399369319827305.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2015
Nephrotoxicity of Chemotherapy Agents
Valika A, Shirali A. Nephrotoxicity of Chemotherapy Agents. 2015, 65-91. DOI: 10.1007/978-1-4939-2659-6_4.Peer-Reviewed Original ResearchChemotherapy agentsAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsChemotherapy-induced nephrotoxicityIntrinsic renal injurySite-specific injuryAcute tubular necrosisGrowth factor agentsGlomerular endothelial damageAdverse drug effectsDistinct clinical syndromeFactor agentsCrystal nephropathyHemodynamic statusPatient characteristicsRenal injuryTubular necrosisEndothelial damageKidney functionClinical syndromeVascular injuryKidney microenvironmentMalignant diseaseGlomerular diseaseDrug effects
2004
The Relationship Between Number of Medications and Weight Loss or Impaired Balance in Older Adults
Agostini JV, Han L, Tinetti ME. The Relationship Between Number of Medications and Weight Loss or Impaired Balance in Older Adults. Journal Of The American Geriatrics Society 2004, 52: 1719-1723. PMID: 15450051, DOI: 10.1111/j.1532-5415.2004.52467.x.Peer-Reviewed Original ResearchConceptsImpaired balanceOdds ratioWeight lossCumulative medication exposureNumber of medicationsAdjusted odds ratioNumber of hospitalizationsAdverse drug effectsCommunity-dwelling residentsAdverse drug outcomesTotal drug useMedication exposureMore medicationsIndividual medicationsCommon manifestationChronic diseasesChronic illnessLongitudinal cohortMedicationsDepressive symptomsDrug effectsCognitive impairmentDrug useHearing impairmentExtensive adjustment
1993
Successful Treatment of Cystinuria With Captopril
Perazella M, Buller G. Successful Treatment of Cystinuria With Captopril. American Journal Of Kidney Diseases 1993, 21: 504-507. PMID: 8488818, DOI: 10.1016/s0272-6386(12)80396-9.Peer-Reviewed Original ResearchConceptsIntolerable side effectsAdverse drug effectsAutosomal recessive hereditary disorderUrinary cystine excretionRecessive hereditary disorderOral alkaliRecurrent nephrolithiasisCystine excretionAttendant complicationsSuccessful treatmentCystine solubilityDrug managementTraditional therapiesDrug effectsSide effectsCystinuric patientsD-penicillamineHereditary disorderCaptoprilPatientsCystinuriaNephrolithiasisMarked declineTraditional managementComplications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply